# Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)

> **NCT04031898** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 896 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **OTHER:** Non Interventional

## Key facts

- **NCT ID:** NCT04031898
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-07
- **Primary completion:** 2019-12-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 896 (ACTUAL)
- **Last updated:** 2020-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04031898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04031898, "Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04031898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*